1053655-66-5

Basic information

• Product Name: 7-Bromo[1,2,4]triazolo[1,5-a]pyridine
• Synonyms: 7-Bromo[1,2,4]triazolo[1,5-a]pyridine;7-Bromo[1,2,4]triazolo[1,...;7-broMo-[1;[1,2,4]Triazolo[1,5-a]pyridine, 7-bromo-
• CAS NO: 1053655-66-5
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02006
• Product Categories: Heterocycle-Pyridine series
• Mol File: 1053655-66-5.mol

Chemical Properties

• Appearance: /
• Density: 1.89±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 1.76±0.30(Predicted)
• CAS DataBase Reference: 7-Bromo[1,2,4]triazolo[1,5-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo[1,2,4]triazolo[1,5-a]pyridine(1053655-66-5)
• EPA Substance Registry System: 7-Bromo[1,2,4]triazolo[1,5-a]pyridine(1053655-66-5)

Safety Data

• Hazardous Substances Data: 1053655-66-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo[1,2,4]triazolo[1,5-a]pyridine is used as a building block for the synthesis of various pharmaceuticals due to its versatile nature and potential therapeutic applications. Its incorporation into drug molecules can enhance their efficacy and target specific biological pathways.
Used in Agrochemical Industry:
7-Bromo[1,2,4]triazolo[1,5-a]pyridine is used as a building block in the development of agrochemicals, such as pesticides and herbicides. Its antiviral and antibacterial properties can contribute to the creation of more effective and targeted agrochemicals for crop protection.
Used in Chemical Compound Production:
7-Bromo[1,2,4]triazolo[1,5-a]pyridine is used as an intermediate in the production of various other chemical compounds. Its unique structure and properties make it a valuable component in the synthesis of a wide range of chemicals for different applications.
Used in Medicinal Chemistry Research:
7-Bromo[1,2,4]triazolo[1,5-a]pyridine is used as a subject of study in medicinal chemistry research to explore its potential applications and biological activities. Researchers investigate its interactions with biological targets and evaluate its efficacy in treating various diseases and conditions.

Upstream product

• 64-18-6 formic acid 
• 1202704-61-7 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate 
• 84249-14-9 2-amino-4-bromopyridine 

Downstream Products

• 1201643-69-7 [1,2,4]triazolo[1,5-a]pyridin-6-ylboronic acid 
• 1210048-18-2 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine 
• 1202701-61-8 (R)-3-(3-fluoro-4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one 
• 1202701-54-9 (S)-(N-3-(3-fluoro-4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methylacetamide 

Relevant articles and documents

FUSED RING HETEROARYL COMPOUNDS AS ALK4/5 INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of ALK5 and/or ALK4 and are useful in the treatment of pulmonary fibrosis, NASH, obesity, diabetes, cancers and other inflammation.

OXAZOLIDINONE DERIVATIVE HAVING FUSED RING

The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): or a pharmaceutically acceptable salt or solvate thereof; wherein ring A is ring B is a benzene ring optionally substituted with lower alkyl; ring C is an optionally substituted six-membered heterocycle containing at least one nitrogen atom and one to three double bond(s) in the ling wherein the atom at the point of attachment to ring B is a carbon atom; ring D is an optionally substituted five-membered ring containing one or two double bond(s) in the ring; A1 and A2 are independently nitrogen or carbon; m is 0 or 1; R represents H, —NHC(═O)RA, —NHC(═S)RA, —NH-het1, —O-het1, —S-het1, —S(═O)-het1, —S(═O)2-het1, het2, —CONHRA, —OH, lower alkyl, lower alkoxy or lower alkenyl; and het1 and het2 are independently a heterocyclic group; with the proviso that the fused ring C-D is not

SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF

The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.